SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000926617-24-000019
Filing Date
2024-04-01
Accepted
2024-03-29 19:14:24
Documents
16
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A awh-20231231xdef14a.htm   iXBRL DEF 14A 1918617
2 GRAPHIC awh-20231231xdef14ag001.jpg GRAPHIC 78123
3 GRAPHIC awh-20231231xdef14ag002.jpg GRAPHIC 87687
  Complete submission text file 0000926617-24-000019.txt   3930118

Data Files

Seq Description Document Type Size
4 EX-101.SCH awh-20231231.xsd EX-101.SCH 6066
5 EX-101.DEF awh-20231231_def.xml EX-101.DEF 6075
6 EX-101.LAB awh-20231231_lab.xml EX-101.LAB 34821
7 EX-101.PRE awh-20231231_pre.xml EX-101.PRE 20067
19 EXTRACTED XBRL INSTANCE DOCUMENT awh-20231231xdef14a_htm.xml XML 679116
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34810 | Film No.: 24805148
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)